Silence Therapeutics plc
(SLN)Financial Statements · SEC EDGAR XBRL
Revenue
$559K
-98.7%
Net Income
-$88.6M
-95.6%
EPS
$-0.63
-90.9%
Gross Margin
61.5%
Op. Income
-$91.1M
-43.8%
FCF
-$62.3M
+8.1%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Research & Development
Operating Income
Non-Operating Income/Expense
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)